Extended Data Table 1:

Statistical analysis of 136 patients treated at the University of Colorado with venetoclax and azacitidine. Univariate analysis of variables listed with odds ratio and p value of variable.

Predictor	Value	Odds Ratio with 95% Confidence Interval	P-value
Age (median)	70.5 years	0.974 (0.95, 1.00)	0.0773
Sex	Male=67 (49.3%) Female=69 (50.7%)	1.521 (0.64, 3.61)	0.3411
Prior Therapy	28 (20.6%)	4.012 (1.58, 10.2)	0.0036
SWOG Cytogenetic Risk Group	Favorable=0 (0%) Intermediate=61 (45.2) Unfavorable=62 (45.9%) Unknown=12 (8.9%)	Unfavorable vs intermediate=4.580 (1.58, 13.3)	0.0804
FLT3 ITD	29 (21.3%)	0.853 (0.29, 2.50)	0.7722
NPM1	32 (23.5%)	0.364 (010, 1.31)	0.1208
IDH1/IDH2	33 (24.3%)	0.212 (005, 0.95)	0.0431
ASXL1	33 (24.3)	0.922 (0.34, 2.53)	0.8752
PTPN11	8 (5.9%)	4.818 (1.12, 20.7)	0.0348
RAS Pathway Mutation	21 (15.4%)	3.316 (1.20, 9.14)	0.0205
TP53	18 (13.2%)	1.247 (0.37, 4.16)	0.7195
ELN Risk Group	Adverse=95 (70.4%) Intermediate=20 (14.8%) Favorable=20 (14.8%)	Adverse vs intermediate=1.708 (0.46, 6.37)	0.0787

SWOG=Southwest Oncology Group; FLT3= Fms-like tyrosine kinase 3; NPM1=nucleophosmin; IDH=isocitrate dehydrogenase; ASXL1=additional sex combs like 1; PTPN11=tyrosine-protein phosphatase non-receptor type 11; RAS=retrovirus-associated DNA sequences; TP53=tumor protein 53; ELN=European Leukemia Network